China Journal of Leprosy and Skin Diseases ›› 2022, Vol. 38 ›› Issue (9): 589-593.doi: 10.12144/zgmfskin202209589

• Original Articles • Previous Articles     Next Articles

Analysis of 163 patients with systemic sclerosis

CAI Jinyun1，2, FU Ping1, SUN Ruixi1, CUN Xingzhu1, XIONG Ruifang1   

  1. 1 Department of Rheumatology, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China;2 Department of Rheumatology, Panzhihua Central Hospital, Panzhihua 617000, China
  • Online:2022-09-15 Published:2022-07-13

PDF (PC)

391

Like

Abstract:

The data of 163 patients with systemic sclerosis (SSc) were analyzed retrospectively, including subtype, clinical manifestation and treatment. Of 163 patients, 95 were dcSSc, 49 were lcSSc, 14 were overlap syndrome, 4 were UCTD, 1 was sine scleroderma. The dermatologic manifestations included swelling (18 cases), hardening (106 cases), atrophy (11 cases). The average score of mRSS (the modified Rodnan skin score) was 12.0. Many organ systems were affected and Raynaud phenomenon (51.0%) was the most common. Multivariate logistic regression showed  the high level of globulin was an independent risk factor of SSc involved hematologic system. 150 patients were treated with glucocorticoid combined with disease-modifying antirheumatic drugs (DMARDs) and 13 patients were treated with glucocorticoid combined with DMARDs and tocilizumab and those method showed some efficacy.

［Key words］systemic sclerosis; blood; tocilizumab; risk factor

Key words: systemic sclerosis, blood, tocilizumab, risk factor